Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]
Discontinued
Reference number: GID-TA10499
Following on from information provided to NICE by the company in December 2020, the appraisal of Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.